D-420720, a novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor: Structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition

Henry J. Tsai, Shan Yen Chou, Shih Hsien Chuang, Chien Cheng Chen, Feng Lin Hsu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are two incretin peptide hormones secreted from the intestine to synergize insulin's function at lowering blood glucose. The effects of GLP-1 or GIP administration are short-lived because they are rapidly inactivated by circulating dipeptidyl peptidase IV (DPP-IV). Therefore, DPP-IV inhibitors have been suggested to be a new class of molecule for treating hyperglycemic conditions in diabetic patients. The recent approval of Merck's Sitagliptin (a DPP-IV-specific inhibitor) indicates that DPP-IV inhibition is a good target for new therapeutic agent development. The present study was conducted to evaluate the efficacies of a series of dipeptidyl derivatives with a sulfonamide moiety as DPP-IV inhibitors. Among these compounds, D-420720 was a potent inhibitor (Ki = 39 nM), with a selectivity of 9160-fold over the DPP-II isozyme and elicits a hypoglycemic effect on oral glucose tolerance test with normal male ICR mice.

Original languageEnglish
Pages (from-to)514-519
Number of pages6
JournalDrug Development Research
Volume69
Issue number8
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl Peptidase 4
Sulfonamides
Structure-Activity Relationship
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
Blood Glucose
Incretins
Inbred ICR Mouse
Peptide Hormones
Glucose Tolerance Test
Hypoglycemic Agents
Isoenzymes
Intestines
Diabetes Mellitus
Homeostasis
Chronic Disease
Glucose
Therapeutics

Keywords

  • Diabetes
  • Dipeptidyl peptidase IV
  • Inhibitor
  • Sulfonamide

ASJC Scopus subject areas

  • Drug Discovery

Cite this

D-420720, a novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor : Structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition. / Tsai, Henry J.; Chou, Shan Yen; Chuang, Shih Hsien; Chen, Chien Cheng; Hsu, Feng Lin.

In: Drug Development Research, Vol. 69, No. 8, 12.2008, p. 514-519.

Research output: Contribution to journalArticle

@article{d19450fa62c34f18ac390a966977cbce,
title = "D-420720, a novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor: Structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition",
abstract = "Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are two incretin peptide hormones secreted from the intestine to synergize insulin's function at lowering blood glucose. The effects of GLP-1 or GIP administration are short-lived because they are rapidly inactivated by circulating dipeptidyl peptidase IV (DPP-IV). Therefore, DPP-IV inhibitors have been suggested to be a new class of molecule for treating hyperglycemic conditions in diabetic patients. The recent approval of Merck's Sitagliptin (a DPP-IV-specific inhibitor) indicates that DPP-IV inhibition is a good target for new therapeutic agent development. The present study was conducted to evaluate the efficacies of a series of dipeptidyl derivatives with a sulfonamide moiety as DPP-IV inhibitors. Among these compounds, D-420720 was a potent inhibitor (Ki = 39 nM), with a selectivity of 9160-fold over the DPP-II isozyme and elicits a hypoglycemic effect on oral glucose tolerance test with normal male ICR mice.",
keywords = "Diabetes, Dipeptidyl peptidase IV, Inhibitor, Sulfonamide",
author = "Tsai, {Henry J.} and Chou, {Shan Yen} and Chuang, {Shih Hsien} and Chen, {Chien Cheng} and Hsu, {Feng Lin}",
year = "2008",
month = "12",
doi = "10.1002/ddr.20278",
language = "English",
volume = "69",
pages = "514--519",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - D-420720, a novel orally active sulfonamide compound dipeptidyl peptidase IV inhibitor

T2 - Structure and activity relationship of arylsulfonamide to dipeptidyl peptidase IV inhibition

AU - Tsai, Henry J.

AU - Chou, Shan Yen

AU - Chuang, Shih Hsien

AU - Chen, Chien Cheng

AU - Hsu, Feng Lin

PY - 2008/12

Y1 - 2008/12

N2 - Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are two incretin peptide hormones secreted from the intestine to synergize insulin's function at lowering blood glucose. The effects of GLP-1 or GIP administration are short-lived because they are rapidly inactivated by circulating dipeptidyl peptidase IV (DPP-IV). Therefore, DPP-IV inhibitors have been suggested to be a new class of molecule for treating hyperglycemic conditions in diabetic patients. The recent approval of Merck's Sitagliptin (a DPP-IV-specific inhibitor) indicates that DPP-IV inhibition is a good target for new therapeutic agent development. The present study was conducted to evaluate the efficacies of a series of dipeptidyl derivatives with a sulfonamide moiety as DPP-IV inhibitors. Among these compounds, D-420720 was a potent inhibitor (Ki = 39 nM), with a selectivity of 9160-fold over the DPP-II isozyme and elicits a hypoglycemic effect on oral glucose tolerance test with normal male ICR mice.

AB - Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are two incretin peptide hormones secreted from the intestine to synergize insulin's function at lowering blood glucose. The effects of GLP-1 or GIP administration are short-lived because they are rapidly inactivated by circulating dipeptidyl peptidase IV (DPP-IV). Therefore, DPP-IV inhibitors have been suggested to be a new class of molecule for treating hyperglycemic conditions in diabetic patients. The recent approval of Merck's Sitagliptin (a DPP-IV-specific inhibitor) indicates that DPP-IV inhibition is a good target for new therapeutic agent development. The present study was conducted to evaluate the efficacies of a series of dipeptidyl derivatives with a sulfonamide moiety as DPP-IV inhibitors. Among these compounds, D-420720 was a potent inhibitor (Ki = 39 nM), with a selectivity of 9160-fold over the DPP-II isozyme and elicits a hypoglycemic effect on oral glucose tolerance test with normal male ICR mice.

KW - Diabetes

KW - Dipeptidyl peptidase IV

KW - Inhibitor

KW - Sulfonamide

UR - http://www.scopus.com/inward/record.url?scp=58449107784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449107784&partnerID=8YFLogxK

U2 - 10.1002/ddr.20278

DO - 10.1002/ddr.20278

M3 - Article

AN - SCOPUS:58449107784

VL - 69

SP - 514

EP - 519

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 8

ER -